GGrantIndex
← Leaderboards

Jenny E. Kanter

University Of Washington

$4,494,120
Attributed
$6,653,801
Total exposure
5
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY202025
$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,653,801 · 5

By mechanism

R01$5,328,878 · 2
P01$1,272,651 · 2
P30$52,272 · 1

Top collaborators

Most similar at University Of Washington

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Cells

Research focus

CellsAtherosclerosisMacrophageDiabetes MellitusComplementLipoproteinsTriglyceridesCardiovascular DiseasesMyeloid CellsMouse ModelAffectTherapeutic TargetPreventIn VitroLipidsCause Of DeathPlasmaEndothelial CellsResidual StateInflammatoryArterial Fatty StreakCardiovascular Disorder RiskAccelerationHistologic

Grant awards (18)

Role of inflammation in intraplaque hemorrhage pathogenesis$812,944
R01 · FY2025 · HL
Core C: Atherosclerosis and bioinformatics core$301,110
P01 · FY2025 · HL · contact PI
Role of inflammation in intraplaque hemorrhage pathogenesis$798,845
R01 · FY2024 · HL
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$372,768
R01 · FY2024 · DK · contact PI
Core C: Myeloid cell and atherosclerosis core$203,139
P01 · FY2024 · HL · contact PI
Role of inflammation in intraplaque hemorrhage pathogenesis$807,682
R01 · FY2023 · HL
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$388,300
R01 · FY2023 · DK · contact PI
Core C: Myeloid cell and atherosclerosis core$188,723
P01 · FY2023 · HL · contact PI
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$98,037
R01 · FY2023 · DK · contact PI
Role of inflammation in intraplaque hemorrhage pathogenesis$820,050
R01 · FY2022 · HL
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$388,300
R01 · FY2022 · DK · contact PI
Core C: Myeloid cell and atherosclerosis core$188,210
P01 · FY2022 · HL · contact PI
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$65,352
R01 · FY2022 · DK · contact PI
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$388,300
R01 · FY2021 · DK · contact PI
Core C: Myeloid cell and atherosclerosis core$188,319
P01 · FY2021 · HL · contact PI
Enrichment Program$52,272
P30 · FY2021 · DK · contact PI
APOC3 mediated dyslipidemia in diabetic kidney disease and atherosclerosis$388,300
R01 · FY2020 · DK · contact PI
Core C: Myeloid cell and atherosclerosis core$203,150
P01 · FY2020 · HL · contact PI